Voyager Therapeutics, Inc. (VYGR)

Market Cap	419.20M
Revenue (ttm)	250.01M
Net Income (ttm)	132.33M
Shares Out	54.30M
EPS (ttm)	2.97
PE Ratio	2.61
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,548
Open	7.60
Previous Close	7.57
Day's Range	7.57 - 7.78
52-Week Range	6.06 - 14.34
Beta	0.95
Analysts	Strong Buy
Price Target	18.57 (+139.92%)
Earnings Date	May 7, 2024

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therap...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 162
• Stock Exchange: NASDAQ
• Ticker Symbol: VYGR

Analyst Forecast

According to 7 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price forecast is $18.57, which is an increase of 139.92% from the latest price.

Price Target

$18.57

(139.92% upside)

Analyst Consensus: Strong Buy